Francesco Leone

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 984 citations · Full text

Oncology, Medicine, Pathology +5

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi et al. · Modern Pathology · 2015 · 309 citations · Full text

Her2 Scoring System, Colorectal Surgery, Medicine +7

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

Massimo Aglietta, Carlo Barone, M. B. Sawyer et al. · Annals of Oncology · 2014 · 216 citations · Full text

Escalation Trial, Oncology, Pancreatic Cancer +8

Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study

Wouter Froyman, C. Landolfo, B. De Cock et al. · The Lancet Oncology · 2019 · 182 citations · Full text

2-Year Interim Analysis, Cancer Risk, Medicine +9

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Andrea Sartore‐Bianchi, Sara Lonardi, Cosimo Martino et al. · ESMO Open · 2020 · 175 citations · Full text

Oncology, Colorectal Cancer, Pathology +4